We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GeneNews Presents Results of Study on Cost-Effectiveness of ColonSentry™
News

GeneNews Presents Results of Study on Cost-Effectiveness of ColonSentry™

GeneNews Presents Results of Study on Cost-Effectiveness of ColonSentry™
News

GeneNews Presents Results of Study on Cost-Effectiveness of ColonSentry™

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GeneNews Presents Results of Study on Cost-Effectiveness of ColonSentry™"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GeneNews Limited has announced that it is presenting results of a health economic analysis of the ColonSentry™ test as a screening tool for colorectal cancer. The results are being presented at the Canadian Agency for Drugs and Technologies in Health Symposium in Ottawa, Ontario from April 5-7, 2009.

The abstract entitled, "The Cost-Effectiveness of a Blood Test for Colorectal Cancer Screening" demonstrated that the ColonSentry test detected more early-stage colorectal cancers, saved lives, and lowered the costs associated with late-stage colorectal cancer compared to the fecal occult blood test (FOBT) or no screening.

The results of the decision-analytic model were presented in terms of quality-adjusted life-years (QALY), a standard measure which takes into account both the quantity and quality of life lived. According to GeneNews Limited, from the healthcare perspective, the ColonSentry test was cost-effective versus no screening ($41,227/QALY) and FOBT ($47,699/QALY). For private payers, ColonSentry saved more lives and cost less than FOBT (-$40,124/QALY) or no screening (-$34,726/QALY).

The results of this analysis will also be presented at the Canadian Association for Population Therapeutics Annual Conference held from April 19 - 21, 2009 in Montreal, Quebec. Following this conference, the abstract will be published in The Canadian Journal of Clinical Pharmacology.
Advertisement